By ONN Staff
Articles
Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance
April 21, 2022
Article
PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.
2022 ASCO Gastrointestinal Cancers Symposium Highlights
April 20, 2022
Article
Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.
Remembering Michael J. Hennessy Sr
February 23, 2022
Article
Hennessy spent his career turning his passion for building businesses and creating jobs into a run of successful ventures and brands.
SABCS 2021 Highlights & Conclusions
February 13, 2022
Article
Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.
63rd American Society of Hematology Annual Meeting and Exposition: Major Nurse Takeaways
February 12, 2022
Article
Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.
Voices Behind the Mask: Oncology Nurses Speak Out About Their COVID-19 Experiences
January 10, 2022
Article
Seasoned oncology nurses share how the COVID-19 pandemic has affected the standard of care at their institution, the consequences of the staffing shortage, and how they believe the oncology community can work together to create a better working environment.
Continuing Education: December 2021
December 23, 2021
Article
CE lesson worth 0.5 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.
Continuing Education: October 2021
October 22, 2021
Article
CE lesson worth 0.5 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.
Continuing Education: August 2021
August 22, 2021
Article
CE lesson worth 0.5 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.
FDA Approves Lurbinectedin for Metastatic Small Cell Lung Cancer
June 16, 2020
Article
The FDA approved lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.